What is INTERPACE BIOSCIENCES NEW's earnings per share (EPS)?

INTERPACE BIOSCIENCES NEW (IDXG) reported diluted earnings per share of $0.89 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

INTERPACE BIOSCIENCES NEW (IDXG) Financials

IDXG

Trailing 12 months to June 30, 2026

Revenue $36.1M -20.5% YoY

Net Income $24.5M +436.4% YoY

EPS (Diluted) $0.89 FY2025 annual

Free Cash Flow $4.1M YoY not available

Market Cap $36.2M as of Oct 12, 2026

Price / Sales 1.0x on $36.1M revenue, trailing 12 months to June 30, 2026

Price / Earnings 1.5x on $24.5M net income, trailing 12 months to June 30, 2026

Price / Book 1.6x on $23.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 10, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IDXG SEC filings page.

INTERPACE BIOSCIENCES NEW (IDXG) reported $36.1M in revenue over the twelve months to Jun 30, 2026, down 20.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IDXG FY2025 2026-10-04

2025 shows a smaller operating business with improving cash generation, but reported profit was dominated by a large tax benefit.

The $21.2M tax benefit made net income far exceed operating income, while operating cash flow was $5.8M, much closer to the operating result. That gap means reported earnings overstated recurring operating performance, even though cash conversion remained positive.

Revenue fell from $46.9M in FY2024 to $38.7M in FY2025 while operating margin narrowed from 17.3% to 10.6%. Because gross margin also slipped, the deterioration reaches beyond overhead and does not resemble scale-driven expansion.

Liabilities fell from $17.0M to $11.5M while equity moved from negative to positive, lifting the current ratio to 1.9x. That balance-sheet repair coincided with shares outstanding rising from 4.4M to 27.7M, so the stronger capitalization should be read alongside a much larger share count.

Financial Health Signals

Financial health score not available

INTERPACE BIOSCIENCES NEW does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-5.12

INTERPACE BIOSCIENCES NEW scores -5.12, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($36.2M) relative to total liabilities ($11.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

INTERPACE BIOSCIENCES NEW passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.24x

For every $1 of reported earnings, INTERPACE BIOSCIENCES NEW generates $0.24 in operating cash flow ($5.8M OCF vs $24.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe

24.31x

INTERPACE BIOSCIENCES NEW earns $24.31 in operating income for every $1 of interest expense ($4.1M vs $168K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$9.1M

YoY-1.1%

QoQ+1.1%

5Y CAGR-3.9%

10Y CAGR+9.7%

INTERPACE BIOSCIENCES NEW generated $9.1M in revenue in Q2 2026. This represents a decrease of 1.1% from the same quarter a year earlier. Against the prior quarter it is up 1.1%.

EBITDA

$448K

YoY+222.1%

QoQ-63.9%

INTERPACE BIOSCIENCES NEW's EBITDA was $448K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 222.1% from the same quarter a year earlier. Against the prior quarter it is down 63.9%.

Net Income

$158K

YoY+124.7%

QoQ-78.1%

INTERPACE BIOSCIENCES NEW reported $158K in net income in Q2 2026. This represents an increase of 124.7% from the same quarter a year earlier. Against the prior quarter it is down 78.1%.

EPS (Diluted)

$0.01

INTERPACE BIOSCIENCES NEW earned $0.01 per diluted share (EPS) in Q2 2026.

Cash & Balance Sheet

Free Cash Flow

$41K

QoQ-71.1%

INTERPACE BIOSCIENCES NEW generated $41K in free cash flow in Q2 2026, representing cash available after capex. Against the prior quarter it is down 71.1%.

Cash & Debt

$2.7M

YoY+435.5%

QoQ+1.5%

5Y CAGR-6.6%

10Y CAGR-1.2%

INTERPACE BIOSCIENCES NEW held $2.7M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

28M

5Y CAGR+46.1%

10Y CAGR+4.3%

INTERPACE BIOSCIENCES NEW had 28M shares outstanding in Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

61.9%

YoY+4.8pp

QoQ-3.5pp

5Y change+13.9pp

10Y change+12.9pp

INTERPACE BIOSCIENCES NEW's gross margin was 61.9% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 4.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.5 percentage points.

Operating Margin

3.5%

YoY+8.6pp

QoQ-8.9pp

5Y change+29.6pp

10Y change+83.6pp

INTERPACE BIOSCIENCES NEW's operating margin was 3.5% in Q2 2026, reflecting core business profitability. This is up 8.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.9 percentage points.

Net Margin

1.7%

YoY+8.7pp

QoQ-6.3pp

5Y change+32.6pp

10Y change+80.5pp

INTERPACE BIOSCIENCES NEW's net profit margin was 1.7% in Q2 2026, showing the share of revenue converted to profit. This is up 8.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.3 percentage points.

Return on Equity

0.7%

QoQ-2.4pp

INTERPACE BIOSCIENCES NEW's ROE was 0.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is down 2.4 percentage points.

Capital Allocation

R&D Spending

$149K

YoY-13.9%

QoQ-2.6%

5Y CAGR-18.9%

10Y CAGR-8.4%

INTERPACE BIOSCIENCES NEW invested $149K in research and development in Q2 2026. This represents a decrease of 13.9% from the same quarter a year earlier. Against the prior quarter it is down 2.6%.

Capital Expenditures

$57K

QoQ-59.6%

INTERPACE BIOSCIENCES NEW invested $57K in capex in Q2 2026, funding long-term assets and infrastructure. Against the prior quarter it is down 59.6%.

Share Buybacks

Not reported for Q2 2026.

IDXG Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IDXG quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$36.1M	$38.7M-17.5%	$46.9M+17.2%	$40.0M+25.7%	$31.8M-3.9%	$33.1M+2.2%	$32.4M+33.8%	$24.2M+10.6%	$21.9M+37.7%	$15.9M+21.5%	$13.1M+38.7%	$9.4M+539.9%	$1.5M-99.0%	$146.5M+15.5%	$126.9M-19.3%	$157.3M
Cost of Revenue	$13.1M	$14.6M-14.1%	$17.0M+13.5%	$15.0M+10.1%	$13.6M-4.9%	$14.3M-34.0%	$21.7M+36.4%	$15.9M+55.8%	$10.2M+38.6%	$7.4M+10.8%	$6.6M-3.9%	$6.9M+445.0%	$1.3M	N/A	N/A	N/A
Gross Profit	$23.0M	$24.1M-19.4%	$29.9M+19.4%	$25.1M+37.4%	$18.2M-3.0%	$18.8M+75.3%	$10.7M+28.7%	$8.3M-28.8%	$11.7M+37.0%	$8.5M+32.5%	$6.4M+155.5%	$2.5M+1124.3%	$206K-99.1%	$23.5M-12.5%	$26.9M-17.3%	$32.5M
R&D Expenses	$594K	$642K-5.0%	$676K+6.3%	$636K-9.5%	$703K-52.9%	$1.5M-46.6%	$2.8M-0.5%	$2.8M+32.3%	$2.1M+45.4%	$1.5M-11.3%	$1.6M-28.1%	$2.3M+798.8%	$255K	N/A	N/A	N/A
SG&A Expenses	$9.7M	$9.5M-0.1%	$9.5M+1.3%	$9.4M-14.7%	$11.0M+2.5%	$10.7M-41.2%	$18.2M+26.7%	$14.4M+65.5%	$8.7M-5.2%	$9.2M-12.9%	$10.5M-37.9%	$16.9M+18.2%	$14.3M-6.2%	$15.3M-7.0%	$16.4M-16.7%	$19.7M
Operating Income	$4.2M	$4.1M-49.6%	$8.1M+105.0%	$4.0M+209.4%	-$3.6M+42.9%	-$6.3M+75.7%	-$26.1M+1.4%	-$26.4M-109.3%	-$12.6M-100.7%	-$6.3M+2.3%	-$6.4M+84.1%	-$40.4M-126.7%	-$17.8M-1140.5%	-$1.4M+94.3%	-$25.2M-436.6%	-$4.7M
EBITDA	N/A	$4.5M-46.4%	$8.4M+68.8%	$5.0M+571.3%	-$1.1M-9.9%	-$962K+95.3%	-$20.6M+6.1%	-$21.9M-148.1%	-$8.8M-239.3%	-$2.6M-32.9%	-$2.0M+94.5%	-$35.4M-129.2%	-$15.4M-128525.0%	-$12K+99.9%	-$23.2M-1300.8%	-$1.7M
Interest Expense	N/A	$168K-73.1%	$625K-30.2%	$896K+5.4%	$850K+271.4%	-$496K-190.3%	$549K+24.8%	$440K+32.9%	$331K-23.6%	$433K-79.8%	$2.1M-42.1%	$3.7M+515.4%	$602K	$0	N/A	N/A
Income Tax	N/A	-$21.2M-530350.0%	$4K-76.5%	$17K-41.4%	$29K+104.1%	-$705K-1430.2%	$53K+289.3%	-$28K-255.6%	$18K+104.6%	-$395K-143.8%	-$162K+98.8%	-$13.1M-161.2%	-$5.0M-2894.4%	$180K-13.5%	$208K+122.2%	-$939K
Net Income	$24.5M	$24.6M+267.2%	$6.7M+235.0%	$2.0M+109.1%	-$22.0M-46.9%	-$14.9M+43.5%	-$26.5M+1.1%	-$26.7M-110.5%	-$12.7M-201.2%	$12.6M+157.1%	-$22.0M-61.5%	-$13.6M+18.8%	-$16.8M-267.3%	-$4.6M+82.1%	-$25.5M-114.3%	-$11.9M
EPS (Basic)	N/A	$5.55+290.8%	$1.42+215.6%	$0.45+108.7%	-$5.18-43.5%	-$3.61	N/A	N/A	N/A	N/A	-$4.63+76.9%	-$20.08-2131.1%	-$0.90-718.2%	-$0.11+93.7%	-$1.75-110.8%	-$0.83
EPS (Diluted)	—	$0.89	$0.40	$0.45+108.7%	-$5.18	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$0.26
Diluted Shares (Avg)	N/A	28M	16M	4M+3.0%	4M+2.5%	4M+2.6%	4M+7.6%	4M	3M-82.1%	16M	2M	2M-89.6%	15M+1.2%	15M+0.9%	15M+1.0%	14M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$9.1M-1.1%	$9.0M-21.6%	$9.2M-25.7%	$8.8M-28.8%	$9.2M-23.3%	$11.5M+13.1%	$12.4M+22.5%	$12.3M+33.6%
Cost of Revenue	$3.5M-12.1%	$3.1M-24.5%	$3.2M-29.4%	$3.3M-24.5%	$4.0M-6.6%	$4.1M+7.2%	$4.5M+18.0%	$4.4M+15.0%
Gross Profit	$5.7M+7.1%	$5.9M-19.9%	$6.0M-23.5%	$5.4M-31.2%	$5.3M-32.4%	$7.4M+16.8%	$7.9M+25.2%	$7.9M+46.8%
R&D Expenses	$149K-13.9%	$153K-13.6%	$142K-26.8%	$150K-24.6%	$173K+18.5%	$177K+29.2%	$194K+27.6%	$199K+33.6%
SG&A Expenses	$3.0M+11.8%	$2.5M-3.9%	$2.2M-13.9%	$2.1M-19.0%	$2.7M+24.3%	$2.5M+13.9%	$2.6M+38.7%	$2.5M+19.5%
Operating Income	$321K+168.6%	$1.1M-38.6%	$1.6M-23.4%	$1.1M-50.2%	-$468K-117.8%	$1.8M+64.2%	$2.1M+38.3%	$2.3M+458.5%
EBITDA	$448K+222.1%	$1.2M-35.5%	$1.7M-21.4%	$1.3M-47.4%	-$367K-113.6%	$1.9M+65.0%	$2.2M	$2.4M+266.0%
Interest Expense	N/A	N/A	$11K-90.1%	$30K-78.7%	$49K-72.2%	$78K-60.4%	$111K-47.9%	$141K-38.7%
Income Tax	$64K	$302K+1577.8%	N/A	-$11K-375.0%	N/A	$18K+350.0%	-$8K-260.0%	$4K0.0%
Net Income	$158K+124.7%	$721K-56.2%	$22.7M+1107.1%	$911K-45.6%	-$640K-126.3%	$1.6M+132.6%	$1.9M+68.8%	$1.7M+1001.1%
EPS (Basic)	$0.01+107.1%	$0.03-91.9%	$5.12+1500.0%	$0.21-44.7%	-$0.14-125.0%	$0.37+131.3%	$0.32+33.3%	$0.38+1050.0%
EPS (Diluted)	$0.01	$0.03	$0.82	$0.03	-$0.14-125.5%	$0.06	-$0.69-376.0%	$0.38+1050.0%
Diluted Shares (Avg)	28M	28M	N/A	28M	4M+0.5%	28M	N/A	4M+2.4%

IDXG Balance Sheet

IDXG quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$33.8M+128.8%	$14.8M+12.8%	$13.1M-17.9%	$16.0M-58.4%	$38.4M-15.9%	$45.7M-11.4%	$51.5M+65.6%	$31.1M-15.0%	$36.6M+45.7%	$25.1M-61.2%	$64.7M-43.8%	$115.2M+66.8%	$69.1M-12.0%	$78.4M-30.8%	$113.4M
Current Assets	$9.9M-15.9%	$11.8M+13.0%	$10.4M-14.3%	$12.2M-0.1%	$12.2M-13.9%	$14.1M-14.5%	$16.5M-6.8%	$17.7M-10.5%	$19.8M+367.2%	$4.2M-77.9%	$19.2M-57.3%	$44.9M-28.5%	$62.7M-12.4%	$71.6M-10.9%	$80.4M
Cash & Equivalents	$2.5M+71.5%	$1.5M-58.2%	$3.5M-27.5%	$4.8M+80.7%	$2.7M-3.6%	$2.8M+19.4%	$2.3M-61.8%	$6.1M-60.1%	$15.2M+2424.8%	$602K-92.8%	$8.3M-64.0%	$23.1M-49.4%	$45.6M-13.5%	$52.8M-18.0%	$64.3M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$106K-0.9%	$107K+3.9%	$103K+12.0%	$92K-27.6%	$127K
Inventory	$1.1M-8.0%	$1.2M-1.3%	$1.2M+0.2%	$1.2M+48.4%	$825K-59.8%	$2.1M+12.4%	$1.8M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$5.6M-33.9%	$8.5M+68.3%	$5.1M+0.9%	$5.0M+7.7%	$4.7M-41.8%	$8.0M-22.3%	$10.3M+9.0%	$9.5M+175.9%	$3.4M+55.6%	$2.2M-21.3%	$2.8M-26.9%	$3.8M+101.6%	$1.9M-82.2%	$10.7M+10.9%	$9.6M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$905K-14.4%	$1.1M+185.7%	$370K-79.3%	$1.8M-53.4%	$3.8M
Goodwill	N/A	N/A	N/A	N/A	$8.4M0.0%	$8.4M0.0%	$8.4M	N/A	N/A	N/A	$0-100.0%	$15.5M	$0-100.0%	$2.5M-86.7%	$18.9M
Total Liabilities	$11.5M-32.5%	$17.0M-75.2%	$68.7M-7.3%	$74.1M-8.4%	$80.8M+8.1%	$74.8M+33.5%	$56.0M+257.2%	$15.7M+14.2%	$13.7M-61.0%	$35.2M-35.5%	$54.7M-42.9%	$95.8M+161.8%	$36.6M-14.6%	$42.8M-20.5%	$53.9M
Current Liabilities	$5.1M-51.9%	$10.6M-7.2%	$11.4M-19.9%	$14.3M-8.9%	$15.7M-14.0%	$18.2M+5.4%	$17.3M+99.5%	$8.7M+7.1%	$8.1M-50.2%	$16.2M-30.5%	$23.4M-30.4%	$33.6M+6.9%	$31.4M-13.7%	$36.4M-21.0%	$46.1M
Non-Current Liabilities	$6.4M-0.3%	$6.4M-88.8%	$57.2M-4.3%	$59.8M-8.3%	$65.2M+15.3%	$56.5M+1136.2%	$4.6M+5.9%	$4.3M+0.7%	$4.3M-77.4%	$19.0M+207.6%	$6.2M-29.9%	$8.8M+70.0%	$5.2M-19.3%	$6.4M-17.4%	$7.8M
Long-Term Debt	N/A	N/A	N/A	$1.8M+255.4%	$520K-85.9%	$3.7M+35.5%	$2.7M	N/A	N/A	$7.9M+9.3%	$7.2M-73.4%	$27.2M	N/A	N/A	N/A
Total Equity	$22.4M+1108.7%	-$2.2M+96.0%	-$55.5M+4.4%	-$58.1M-36.9%	-$42.4M-45.9%	-$29.1M-549.3%	-$4.5M-129.0%	$15.4M-32.5%	$22.9M+326.4%	-$10.1M-200.4%	$10.1M-48.2%	$19.4M-40.2%	$32.5M-8.8%	$35.6M-40.1%	$59.5M
Retained Earnings	-$210.8M+10.4%	-$235.4M+2.8%	-$242.1M+2.8%	-$249.0M-9.7%	-$227.1M-7.0%	-$212.1M-14.2%	-$185.7M-16.8%	-$159.0M-20.6%	-$131.8M-10.2%	-$119.6M-7.5%	-$111.3M-11.4%	-$99.9M-19.2%	-$83.8M-5.8%	-$79.3M-47.5%	-$53.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$34.5M+180.1%	$33.4M+130.5%	$33.8M+128.8%	$12.0M-14.3%	$12.3M-4.9%	$14.5M+19.4%	$14.8M+12.8%	$14.0M-1.5%
Current Assets	$11.0M+15.4%	$10.0M-14.5%	$9.9M-15.9%	$9.1M+0.3%	$9.5M0.0%	$11.7M+23.8%	$11.8M+13.0%	$9.1M-20.4%
Cash & Equivalents	$2.7M+435.5%	$2.6M+121.3%	$2.5M+71.5%	$1.4M+1.6%	$502K+0.4%	$1.2M-57.5%	$1.5M-58.2%	$1.4M-72.2%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.1M+11.5%	$961K-20.5%	$1.1M-8.0%	$1.1M-9.5%	$973K-21.0%	$1.2M+4.8%	$1.2M-1.3%	$1.2M+11.6%
Accounts Receivable	$6.3M-12.7%	$5.9M-32.4%	$5.6M-33.9%	$6.0M-18.2%	$7.2M+16.5%	$8.8M+75.1%	$8.5M+68.3%	$7.3M+51.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$11.3M-16.6%	$10.3M-31.5%	$11.5M-32.5%	$12.3M-80.9%	$13.5M-79.2%	$15.1M-77.5%	$17.0M-75.2%	$64.6M-9.0%
Current Liabilities	$5.0M-30.7%	$4.0M-54.3%	$5.1M-51.9%	$5.9M+0.8%	$7.1M+0.7%	$8.7M-31.1%	$10.6M-7.2%	$5.9M-52.1%
Non-Current Liabilities	$6.4M-0.7%	$6.4M-0.5%	$6.4M-0.3%	$6.4M-89.1%	$6.4M-89.0%	$6.4M-88.2%	$6.4M-88.8%	$58.7M0.0%
Total Equity	$23.2M+2016.2%	$23.1M+4066.0%	$22.4M+1108.7%	-$298K+99.4%	-$1.2M+97.7%	-$582K+98.9%	-$2.2M+96.0%	-$50.5M+10.9%
Retained Earnings	-$209.9M+10.4%	-$210.1M+10.1%	-$210.8M+10.4%	-$233.5M+1.6%	-$234.4M+1.9%	-$233.7M+3.2%	-$235.4M+2.8%	-$237.3M+4.8%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

IDXG Cash Flow Statement

IDXG quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$4.5M	$5.8M+25.5%	$4.6M+22.6%	$3.8M+149.3%	-$7.7M+11.8%	-$8.7M+37.6%	-$14.0M+26.3%	-$19.0M-118.6%	-$8.7M+43.2%	-$15.3M-100.6%	-$7.6M+61.7%	-$19.8M-21.2%	-$16.4M-366.3%	-$3.5M+65.9%	-$10.3M-618.2%	$2.0M
Depreciation & Amortization	N/A	$425K+41.7%	$300K-70.8%	$1.0M-59.9%	$2.6M-52.4%	$5.4M-2.3%	$5.5M+21.6%	$4.5M+19.0%	$3.8M+3.0%	$3.7M-17.7%	$4.5M-10.9%	$5.0M+110.4%	$2.4M+67.8%	$1.4M-29.9%	$2.0M-33.2%	$3.0M
Stock-Based Compensation	N/A	$35K-88.0%	$291K-53.8%	$630K-49.9%	$1.3M+0.2%	$1.3M-42.6%	$2.2M+42.5%	$1.5M-32.4%	$2.3M+114.2%	$1.1M+709.2%	$131K-96.7%	$4.0M+89.1%	$2.1M+23.3%	$1.7M-3.8%	$1.8M-7.5%	$1.9M
Capital Expenditures	$353K	$356K-59.4%	$876K+86.4%	$470K+46.0%	$322K-9.0%	$354K-77.5%	$1.6M+1102.3%	$131K-70.8%	$449K+1448.3%	$29K	N/A	$353K-87.6%	$2.9M+56.8%	$1.8M+63.5%	$1.1M+224.2%	$343K
Free Cash Flow	$4.1M	$5.5M+45.2%	$3.8M+13.6%	$3.3M+141.4%	-$8.0M+11.7%	-$9.1M+41.7%	-$15.6M+18.5%	-$19.1M-109.3%	-$9.1M+40.3%	-$15.3M	N/A	-$20.2M-5.0%	-$19.2M-260.8%	-$5.3M+53.2%	-$11.4M-794.2%	$1.6M
Investing Cash Flow	-$353K	-$356K+59.4%	-$876K-906.9%	-$87K-101.4%	$6.2M+2070.2%	-$315K+80.0%	-$1.6M+88.7%	-$13.9M-3006.2%	-$449K-1448.3%	-$29K	N/A	$26.4M+204.1%	-$25.4M-664.5%	-$3.3M-198.4%	-$1.1M-224.2%	-$343K
Financing Cash Flow	N/A	-$4.4M+23.7%	-$5.8M-15.4%	-$5.0M-267.7%	$3.0M-66.6%	$9.0M-45.9%	$16.6M-43.0%	$29.2M+324066.7%	-$9K-100.0%	$29.9M+29693.1%	-$101K+99.5%	-$21.4M-211.1%	$19.2M+6219.4%	-$314K-101.3%	-$156K-875.0%	-$16K
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$208K-8.8%	$228K-27.4%	$314K+101.3%	$156K+875.0%	$16K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$98K-81.2%	$283K-77.1%	$2.1M+80.6%	$1.9M-8.4%	$520K-63.0%	$1.2M+2229.3%	$1.2M+3.9%	$2.1M+91.5%
Depreciation & Amortization	$127K+25.7%	$118K+24.2%	$118K+24.2%	$111K+30.6%	$101K+50.7%	$95K+82.7%	$95K	$85K-64.6%
Stock-Based Compensation	$4K-55.6%	$4K-73.3%	N/A	$7K-91.9%	$9K-83.0%	$15K-81.0%	N/A	$86K-43.4%
Capital Expenditures	$57K	$141K	$38K-70.5%	$117K-77.6%	N/A	N/A	$129K-9.2%	$522K+243.4%
Free Cash Flow	$41K	$142K	$2.1M+99.1%	$1.8M+14.2%	N/A	N/A	$1.1M+5.7%	$1.6M+67.3%
Investing Cash Flow	-$57K	-$141K	-$38K+70.5%	-$117K+77.6%	N/A	N/A	-$129K+9.2%	-$522K-250.0%
Financing Cash Flow	N/A	N/A	-$1.0M+40.4%	-$900K+40.0%	-$1.0M+49.4%	-$1.5M-150.0%	-$1.7M+32.6%	-$1.5M0.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

IDXG Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IDXG quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	62.3%-1.5pp	63.8%+1.2pp	62.6%+5.3pp	57.3%+0.5pp	56.8%+23.7pp	33.1%-1.3pp	34.4%-19.0pp	53.4%-0.3pp	53.7%+4.5pp	49.3%+22.5pp	26.7%+12.8pp	14.0%-2.1pp	16.0%-5.1pp	21.2%+0.5pp	20.6%
Operating Margin	10.5%-6.7pp	17.3%+7.4pp	9.9%+21.2pp	-11.4%+7.8pp	-19.1%+61.3pp	-80.5%	-109.1%	-57.7%-18.1pp	-39.6%+9.6pp	-49.2%	-428.4%	-1209.4%	-1.0%+18.9pp	-19.9%-16.9pp	-3.0%
Net Margin	63.5%+49.2pp	14.3%+9.3pp	5.0%+74.0pp	-69.0%-23.8pp	-45.1%+36.5pp	-81.6%	-110.4%	-58.0%-137.0pp	79.0%	-168.2%	-144.4%	-1137.6%	-3.1%+17.0pp	-20.1%-12.6pp	-7.6%
Return on Equity	110.0%	N/A	N/A	N/A	N/A	N/A	N/A	-82.2%-137.1pp	54.8%	N/A	-135.3%-49.0pp	-86.3%-72.2pp	-14.1%+57.6pp	-71.6%-51.6pp	-20.0%
Return on Assets	72.7%+27.4pp	45.3%+30.0pp	15.3%+152.7pp	-137.4%-98.5pp	-38.9%+19.0pp	-57.9%-6.0pp	-51.9%-11.1pp	-40.8%-75.1pp	34.3%+121.8pp	-87.5%-66.5pp	-21.0%-6.5pp	-14.5%-7.9pp	-6.6%+25.9pp	-32.5%-22.0pp	-10.5%
Current Ratio	1.94+0.8x	1.11+0.2x	0.91+0.1x	0.85+0.1x	0.780.0x	0.77-0.2x	0.95-1.1x	2.04-0.4x	2.45+2.2x	0.26-0.6x	0.82-0.5x	1.34-0.7x	2.000.0x	1.97+0.2x	1.74
Debt-to-Equity	0.51	N/A	N/A	N/A	N/A	N/A	N/A	1.02+0.4x	0.60	N/A	0.72-0.7x	1.40+0.3x	1.13-0.1x	1.20+0.3x	0.90
Asset Turnover	1.14-2.0x	3.17+0.1x	3.05+1.1x	1.99+1.1x	0.86+0.2x	0.71+0.2x	0.47-0.2x	0.70+0.3x	0.43-0.1x	0.52+0.4x	0.15+0.1x	0.01-2.1x	2.12+0.5x	1.62+0.2x	1.39
FCF Margin	14.1%+6.1pp	8.0%-0.3pp	8.3%+33.5pp	-25.2%+2.2pp	-27.4%+20.6pp	-48.0%+30.8pp	-78.8%-37.1pp	-41.7%+54.5pp	-96.2%	N/A	-214.1%	-1304.5%	-3.6%+5.3pp	-9.0%-10.0pp	1.0%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	61.9%+4.8pp	65.4%+1.4pp	65.5%+1.8pp	62.1%-2.2pp	57.1%-7.7pp	64.0%+2.0pp	63.7%+1.4pp	64.3%+5.8pp
Operating Margin	3.5%+8.6pp	12.4%-3.5pp	17.1%+0.5pp	13.1%-5.6pp	-5.1%-26.9pp	15.9%+4.9pp	16.6%+1.9pp	18.7%+14.2pp
Net Margin	1.7%+8.7pp	8.0%-6.3pp	245.9%	10.4%-3.2pp	-6.9%-27.2pp	14.3%+7.3pp	15.1%+4.2pp	13.6%+15.7pp
Return on Equity	0.7%	3.1%	101.4%	N/A	N/A	N/A	N/A	N/A
Return on Assets	0.5%+5.7pp	2.2%-9.2pp	67.0%+54.3pp	7.6%-4.4pp	-5.2%-24.0pp	11.4%+5.5pp	12.7%+4.2pp	11.9%+13.3pp
Current Ratio	2.22+0.9x	2.51+1.2x	1.94+0.8x	1.540.0x	1.330.0x	1.34+0.6x	1.11+0.2x	1.54+0.6x
Debt-to-Equity	0.49	0.45	0.51	N/A	N/A	N/A	N/A	N/A
Asset Turnover	0.26-0.5x	0.27-0.5x	0.27-0.6x	0.73-0.1x	0.75-0.2x	0.790.0x	0.84+0.1x	0.88+0.2x
FCF Margin	0.4%	1.6%	22.8%+14.3pp	20.8%+7.8pp	N/A	N/A	8.5%-1.3pp	13.0%+2.6pp

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
INTERPACE BIOSCIENCES NEW IDXG	FY2025	$38.7M	$24.6M	63.5%	$36.2M	—
HYPHA LABS, INC. FUNI	FY2025	N/A	N/A	N/A	$639K	—

Where INTERPACE BIOSCIENCES NEW Ranks

Frequently Asked Questions

What is INTERPACE BIOSCIENCES NEW's annual revenue?

INTERPACE BIOSCIENCES NEW (IDXG) reported $38.7M in total revenue for fiscal year 2025. This represents a -17.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is INTERPACE BIOSCIENCES NEW's revenue growing?

INTERPACE BIOSCIENCES NEW (IDXG) revenue declined by 17.5% year-over-year, from $46.9M to $38.7M in fiscal year 2025.

Is INTERPACE BIOSCIENCES NEW profitable?

Yes, INTERPACE BIOSCIENCES NEW (IDXG) reported a net income of $24.6M in fiscal year 2025, with a net profit margin of 63.5%.

What is INTERPACE BIOSCIENCES NEW's EBITDA?

INTERPACE BIOSCIENCES NEW (IDXG) had EBITDA of $4.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is INTERPACE BIOSCIENCES NEW's gross margin?

INTERPACE BIOSCIENCES NEW (IDXG) had a gross margin of 62.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is INTERPACE BIOSCIENCES NEW's operating margin?

INTERPACE BIOSCIENCES NEW (IDXG) had an operating margin of 10.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is INTERPACE BIOSCIENCES NEW's net profit margin?

INTERPACE BIOSCIENCES NEW (IDXG) had a net profit margin of 63.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is INTERPACE BIOSCIENCES NEW's return on equity (ROE)?

INTERPACE BIOSCIENCES NEW (IDXG) has a return on equity of 110.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is INTERPACE BIOSCIENCES NEW's free cash flow?

INTERPACE BIOSCIENCES NEW (IDXG) generated $5.5M in free cash flow during fiscal year 2025. This represents a 45.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is INTERPACE BIOSCIENCES NEW's operating cash flow?

INTERPACE BIOSCIENCES NEW (IDXG) generated $5.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are INTERPACE BIOSCIENCES NEW's total assets?

INTERPACE BIOSCIENCES NEW (IDXG) had $33.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are INTERPACE BIOSCIENCES NEW's capital expenditures?

INTERPACE BIOSCIENCES NEW (IDXG) invested $356K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does INTERPACE BIOSCIENCES NEW spend on research and development?

INTERPACE BIOSCIENCES NEW (IDXG) invested $642K in research and development during fiscal year 2025.

How many shares does INTERPACE BIOSCIENCES NEW have outstanding?

INTERPACE BIOSCIENCES NEW (IDXG) had 28M shares outstanding as of fiscal year 2025.

What is INTERPACE BIOSCIENCES NEW's current ratio?

INTERPACE BIOSCIENCES NEW (IDXG) had a current ratio of 1.94 as of fiscal year 2025, which is generally considered healthy.

What is INTERPACE BIOSCIENCES NEW's debt-to-equity ratio?

INTERPACE BIOSCIENCES NEW (IDXG) had a debt-to-equity ratio of 0.51 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is INTERPACE BIOSCIENCES NEW's return on assets (ROA)?

INTERPACE BIOSCIENCES NEW (IDXG) had a return on assets of 72.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is INTERPACE BIOSCIENCES NEW's P/E ratio?

INTERPACE BIOSCIENCES NEW (IDXG) trades at 1.5x earnings, its market capitalization divided by net income of $24.5M net income, trailing 12 months to June 30, 2026. The market capitalization is $36.2M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is INTERPACE BIOSCIENCES NEW's price-to-sales ratio?

INTERPACE BIOSCIENCES NEW (IDXG) trades at 1.0x sales, its market capitalization divided by revenue of $36.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $36.2M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is INTERPACE BIOSCIENCES NEW's Altman Z-Score?

INTERPACE BIOSCIENCES NEW (IDXG) has an Altman Z-Score of -5.12, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is INTERPACE BIOSCIENCES NEW's Piotroski F-Score?

INTERPACE BIOSCIENCES NEW (IDXG) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are INTERPACE BIOSCIENCES NEW's earnings high quality?

INTERPACE BIOSCIENCES NEW (IDXG) has an earnings quality ratio of 0.24x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can INTERPACE BIOSCIENCES NEW cover its interest payments?

INTERPACE BIOSCIENCES NEW (IDXG) has an interest coverage ratio of 24.31x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.